Lymphocyte function following radioiodine therapy in patients with thyroid carcinoma;lymphozytenfunktion nach radioiodtherapie bei patienten mit schilddrüsenkarzinom

NuklearMedizin

Volumn 50, Issue 5, 2011, Pages 195-203

  Barsegian, V ^a   Muller S P ^b   Horn, P A ^b   Bockisch, A ^b   Lindemann, M ^b  

^a KLINIKUM DORTMUND   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Anti microbial immunity; Elispot; Lymphocyte function; Lymphocyte transformation test; Radioiodine therapy

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; IODINE 131; RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFORMATION TEST; MALE; RADIOISOTOPE THERAPY; THYROID CARCINOMA;

ADULT; AGED; CYTOKINES; FEMALE; HUMANS; IMMUNITY, INNATE; IODINE RADIOISOTOPES; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 80053592008     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/nukmed-04241108     Document Type: Article

References (27)

1. Anderson RE, Lefkovits I. Effects of irradiation on the in vitro immune response. Exp Cell Biol 1980; 48: 255-278.
2. Anderson RE, Warner NL. Ionizing radiation and the immune response. Adv Immunol 1976; 24: 215-335.
3. Apostoloff E, Friedel E, Apostoloff G et al. Cellular immunological reactions in vivo and vitro in higher age. ZFA 1980; 35: 211-213.
4. Belka C, Ottinger H, Kreuzfelder E et al. Impact of localized radiotherapy on blood immune cells counts and function in humans. Radiother Oncol 1999; 50: 199-204.
5. Choi KM, Kang CM, Cho ES et al. Ionizing radiation-induced micronucleus formation is mediated by reactive oxygen species that are produced in a manner dependent on mitochondria, Nox1, and JNK. Oncol Rep 2007; 17: 1183-1188.
6. Dehos G, Hinz G, Schwarz E-R. Changes in number and function of the lymphocyte populations as a biological indicator for ionizing radiation. In: Kaul A, Dehos A, Bögl W et al. (eds). Biological indicators for radiation dose assessment. München: MMV, 1986. 298-301.
7. Federico G, Boni G, Fabiani B et al. No evidence of chromosome damage in children and adolescents with differentiated thyroid carcinoma after receiving 131I radiometabolic therapy, as evaluated by micronucleus assay and microarray analysis. Eur J Nucl Med Mol Imaging 2008; 35: 2113-2121.
8. Furhang EE, Larson SM, Buranapong P et al. Thyroid cancer dosimetry using clearance fitting. J Nucl Med 1999; 40: 131-136.
9. Galdiero M, de Lero GC, Folgore A et al. Effects of irradiation doses on alterations in cytokine release by monocytes and lymphocytes. J Med 1994; 25: 23-40.
10. Gradzka I, Iwanenko T. A Non-radioactive, PFGE-based assay for low levels of DNA double-strand breaks in mammalian cells. DNA Repair (Amst) 2005; 4: 1129-1139.
11. Grosse-Wilde H, Schaefer UW. Radiopathology of Organs and Tissues: Lymphatic System. In: Scherer E, Streffer C, Trott K-R (eds). Medical Radiology. Berlin, Heidelberg: Springer 1991; 171-190.
12. 60Co. Radiat Res 1988; 116: 254-262.
13. James SE, Arlett CF, Green MH et al. Radiosensitiv-ity of human T-lymphocytes proliferating in long term culture. Int J Radiat Biol Relat Stud Phys Chem Med 1983; 44: 417-422.
14. Joseph LJ, Bhartiya US, Raut YS et al. Micronuclei frequency in peripheral blood lymphocytes of thyroid cancer patients after radioiodine therapy and its relationship with metastasis. Mutat Res 2009; 675: 35-40.
15. Lassmann M, Hanscheid H, Chiesa C et al. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging 2008; 35: 1405-1412.
16. Lassmann M, Hanscheid H, Gassen D et al. In vivo formation of gamma-H2AX and 53BP1 DNA repair foci in blood cells after radioiodine therapy of differentiated thyroid cancer. J Nucl Med 2010; 51: 1318-1325.
17. Lindemann M, Barsegian V, Runde V et al. Transfer of humoral and cellular hepatitis B immunity by al-logeneic hematopoietic cell transplantation. Transplantation 2003; 75: 833-838.
18. Lindemann M, Barsegian V, Siffert W et al. Role of G protein beta3 subunit C825T and HLA class II polymorphisms in the immune response after HBV vaccination. Virology 2002; 297: 245-252.
19. Lindemann M, Böhmer J, Zabel M et al. ELISpot: a new tool for the detection of nickel sensitization. Clin Exp Allergy 2003; 33: 992-998.
20. Lindemann M, Schuett P, Moritz T et al. Cellular in vitro immune function in multiple myeloma patients after high-dose chemotherapy and auto-logous peripheral stem cell transplantation. Leukemia 2005; 19: 490-492.
21. Lindemann M, Virchow S, Ramann F et al. The G protein beta3 subunit 825T allele is a genetic marker for enhanced T cell response. FEBS Lett 2001; 495: 82-86.
22. MacKenzie D. Fukushima radioactive fallout nears Chernobyl levels. New Scientist 2011 (cited 2011 August 10). www.webcitation.org/5xRjHTuh3.
23. 188Re-CD66mAb before stem cell transplantation. No increase of proinflammatory cytokine levels of TNF-alpha. Nuklearmedizin 2009; 48: 30-36.
24. Publication 53, Radiation dose to patients from radiopharmaceuticals. In: Annals of the ICRP. Oxford: Pergamon Press, 1987. 31-375.
25. Schrek R, Stefani S. Resistance of phytohaem-agglutinin-treated lymphocytes to X-rays and nitrogen mustard. Nature 1963; 200: 482-483.
26. Ugurel S, Lindemann M, Schadendorf D et al. Altered surface expression patterns of circulating mono-cytes in cancer patients: impaired capacity of T-cell stimulation? Cancer Immunol Immunother 2004; 53: 1051.
27. Watanabe N, Kanegane H, Kinuya S et al. The radio-toxicity of 131I therapy of thyroid cancer: assessment by micronucleus assay of B lymphocytes. J Nucl Med 2004; 45: 608-611.